PolyPid (PYPD) is a Healthcare · Biotechnology company listed on NASDAQ. Price $5.21 (+3.58%), Market cap $0.09B, 52-week low–high $2.54 ~ $5.02.
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. Pol
Financial statements, price targets, institutional (13F) holdings and related news for PolyPid are updated in real time on BlackAll Trade.
PolyPid trades at $5.21 (+3.58%). Real-time quotes and charts are available on BlackAll Trade.
PolyPid has a market cap of about $0.09B.
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to a